Renee is a Director of Clinical Development in Virology who joined Gilead in October 2021 after a 24 ½ year long career in Academia. Renee was a professor of Pharmacy and Medicine at the University of New Mexico where she worked as an Infectious Disease specialist and researcher prior to joining Gilead. At Gilead Renee has been involved in the clinical development of Bulevirtide leading the renal and hepatic impairment Phase 1 studies as study director and medical monitor, the finite therapy Phase 2 MYR204 study and supporting MYR301 and regulatory fillings across the World. She is also the clinical development lead for Hepatitis C.